JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Project Announcements
Messer Plans Berryville, Arkansas, Air Separation Operations
01/16/2025
NewGlobal Ventures Plans Estancia Valley, New Mexico, Canning Operations
01/16/2025
Oxeon Energy Expands Davis County, Utah, Production Operations
01/13/2025
Nucor Towers & Structures Plans Brigham City, Utah, Production Operations
01/13/2025
Canada-Based Markdom Michigan Plastics Plans Charlotte, Michigan, Production Operations
01/13/2025
Japan-Based Nitto Plans Frankfort, Kentucky, Operations
01/12/2025
Most Read
-
2024's Leading Metro Locations: U.S. Cities on the Rise Amid an Economic Reshuffling
Q4 2024
-
The Workforce Factor: How States Are Competing to Build Tomorrow's Talent
Q4 2024
-
Best Practices in Incentives Procurement
Q4 2024
-
Five Strategies to Tackle the Data Center Talent Shortage
Q4 2024
-
Microsoft-Three Mile Island Deal Could Signal Path for Nuclear Power to Strengthen Partnerships with Big Tech
Q4 2024
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Why Decarbonization Goals Start with Site Selection
Q4 2024